1	Interleukin-1	Interleukin-1	B-NP	NN	B-protein	2	NMOD	-1
2	receptor	receptor	I-NP	NN	I-protein	3	NMOD	-1
3	antagonist	antagonist	I-NP	NN	O	4	SUB	-1
4	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	18	inhibits
5	ischaemic	ischaemic	B-NP	JJ	O	7	AMOD	-1
6	and	and	I-NP	CC	O	7	AMOD	-1
7	excitotoxic	excitotoxic	I-NP	JJ	O	9	NMOD	-1
8	neuronal	neuronal	I-NP	JJ	O	9	NMOD	-1
9	damage	damage	I-NP	NN	O	4	OBJ	6	damage
10	in	in	B-PP	IN	O	4	VMOD	-1
11	the	the	B-NP	DT	O	12	NMOD	-1
12	rat	rat	I-NP	NN	O	10	PMOD	-1
13	.	.	O	.	O	4	P	-1

1	Interleukin-1	Interleukin-1	B-NP	NN	B-protein	5	NMOD	-1
2	(	(	O	(	O	4	DEP	-1
3	IL-1	IL-1	B-NP	NN	B-protein	4	DEP	-1
4	)	)	O	)	O	1	NMOD	-1
5	synthesis	synthesis	B-NP	NN	O	9	SUB	9	synthesis
6	in	in	B-PP	IN	O	5	NMOD	-1
7	the	the	B-NP	DT	O	8	NMOD	-1
8	brain	brain	I-NP	NN	O	6	PMOD	-1
9	is	be	B-VP	VBZ	O	0	ROOT	-1
10	stimulated	stimulate	I-VP	VBN	O	9	VC	17	stimulated
11	by	by	B-PP	IN	O	10	VMOD	-1
12	mechanical	mechanical	B-NP	JJ	O	13	NMOD	-1
13	injury	injury	I-NP	NN	O	16	NMOD	-1
14	and	and	I-NP	CC	O	16	NMOD	-1
15	IL-1	IL-1	I-NP	NN	B-protein	16	NMOD	-1
16	mimics	mimic	I-NP	NNS	O	18	NMOD	-1
17	some	some	B-NP	DT	O	18	NMOD	-1
18	effects	effect	I-NP	NNS	O	11	PMOD	0
19	of	of	B-PP	IN	O	18	NMOD	-1
20	injury	injury	B-NP	NN	O	19	PMOD	-1
21	,	,	O	,	O	18	P	-1
22	such	such	B-PP	JJ	O	23	PMOD	-1
23	as	as	I-PP	IN	O	18	NMOD	-1
24	gliosis	gliosis	B-NP	NN	O	26	NMOD	-1
25	and	and	I-NP	CC	O	26	NMOD	-1
26	neovascularization	neovascularization	I-NP	NN	O	23	PMOD	3	neovascularization
27	.	.	O	.	O	9	P	-1

1	We	We	B-NP	PRP	O	2	SUB	-1
2	report	report	B-VP	VBP	O	0	ROOT	-1
3	that	that	B-SBAR	IN	O	2	VMOD	-1
4	neuronal	neuronal	B-NP	JJ	O	5	NMOD	-1
5	death	death	I-NP	NN	O	20	SUB	5	death
6	resulting	result	B-VP	VBG	O	5	NMOD	0
7	from	from	B-PP	IN	O	6	VMOD	-1
8	focal	focal	B-NP	JJ	O	10	NMOD	-1
9	cerebral	cerebral	I-NP	JJ	O	10	NMOD	-1
10	ischaemia	ischaemia	I-NP	NN	O	7	PMOD	-1
11	(	(	O	(	O	19	DEP	-1
12	middle	middle	B-NP	JJ	O	15	NMOD	-1
13	cerebral	cerebral	I-NP	JJ	O	15	NMOD	-1
14	artery	artery	I-NP	NN	O	15	NMOD	-1
15	occlusion	occlusion	I-NP	NN	O	18	NMOD	-1
16	,	,	O	,	O	18	P	-1
17	24	24	B-NP	CD	O	18	NMOD	-1
18	h	h	I-NP	NN	O	19	DEP	-1
19	)	)	O	)	O	10	NMOD	-1
20	is	be	B-VP	VBZ	O	3	SBAR	-1
21	significantly	significantly	I-VP	RB	O	20	VMOD	-1
22	inhibited	inhibit	I-VP	VBN	O	20	VC	18	inhibited
23	(	(	O	(	O	22	VMOD	-1
24	by	by	B-PP	IN	O	22	VMOD	-1
25	50	50	B-NP	CD	O	26	NMOD	-1
26	%	%	I-NP	NN	O	24	PMOD	-1
27	)	)	O	)	O	22	VMOD	-1
28	in	in	B-PP	IN	O	22	VMOD	-1
29	rats	rat	B-NP	NNS	O	28	PMOD	-1
30	injected	inject	B-VP	VBN	O	29	NMOD	19	injected
31	with	with	B-PP	IN	O	30	VMOD	-1
32	a	a	B-NP	DT	O	36	NMOD	-1
33	recombinant	recombinant	I-NP	JJ	O	36	NMOD	-1
34	IL-1	IL-1	I-NP	NN	O	36	NMOD	-1
35	receptor	receptor	I-NP	NN	O	36	NMOD	-1
36	antagonist	antagonist	I-NP	NN	O	31	PMOD	-1
37	(	(	O	(	O	36	NMOD	-1
38	IL-1ra	IL-1ra	B-NP	NN	B-protein	45	NMOD	-1
39	,	,	O	,	O	45	P	-1
40	10	10	B-NP	CD	O	41	NMOD	-1
41	micrograms	microgram	I-NP	NNS	O	45	NMOD	-1
42	,	,	O	,	O	45	P	-1
43	icv	icv	B-NP	NN	O	45	NMOD	-1
44	30	30	I-NP	CD	O	45	NMOD	-1
45	min	min	I-NP	NN	O	37	PMOD	-1
46	before	before	B-PP	IN	O	45	NMOD	-1
47	and	and	O	CC	O	46	PMOD	-1
48	10	10	B-NP	CD	O	49	NMOD	-1
49	min	min	I-NP	NN	O	46	PMOD	-1
50	after	after	B-PP	IN	O	49	NMOD	-1
51	ischaemia	ischaemia	B-NP	NN	O	50	PMOD	-1
52	)	)	O	)	O	49	NMOD	-1
53	.	.	O	.	O	2	P	-1

1	Excitotoxic	Excitotoxic	B-NP	JJ	O	2	NMOD	-1
2	damage	damage	I-NP	NN	O	16	SUB	0
3	due	due	B-PP	JJ	O	2	NMOD	0
4	to	to	B-PP	TO	O	3	AMOD	-1
5	striatal	striatal	B-NP	JJ	O	6	NMOD	-1
6	infusion	infusion	I-NP	NN	O	4	PMOD	19	infusion
7	of	of	B-PP	IN	O	6	NMOD	-1
8	an	an	B-NP	DT	O	10	NMOD	-1
9	NMDA-receptor	NMDA-receptor	I-NP	NN	O	10	NMOD	-1
10	agonist	agonist	I-NP	NN	O	7	PMOD	-1
11	(	(	O	(	O	15	DEP	-1
12	cis-2	cis-2	B-NP	NN	B-DNA	14	NMOD	-1
13	,	,	O	,	O	14	P	-1
14	4-methanoglutamate	4-methanoglutamate	B-NP	NN	O	15	DEP	-1
15	)	)	O	)	O	10	NMOD	-1
16	was	be	B-VP	VBD	O	0	ROOT	-1
17	also	also	I-VP	RB	O	16	VMOD	-1
18	markedly	markedly	I-VP	RB	O	16	VMOD	-1
19	inhibited	inhibit	I-VP	VBD	O	16	VC	0
20	(	(	O	(	O	23	DEP	-1
21	71	71	B-NP	CD	O	22	NMOD	-1
22	%	%	I-NP	NN	O	23	DEP	-1
23	)	)	O	)	O	19	VMOD	-1
24	by	by	B-PP	IN	O	19	VMOD	-1
25	injection	injection	B-NP	NN	O	24	PMOD	19	injection
26	of	of	B-PP	IN	O	25	NMOD	-1
27	the	the	B-NP	DT	O	28	NMOD	-1
28	IL-1ra	IL-1ra	I-NP	NN	B-protein	26	PMOD	-1
29	.	.	O	.	O	16	P	-1

1	These	These	B-NP	DT	O	2	NMOD	-1
2	data	datum	I-NP	NNS	O	3	SUB	-1
3	indicate	indicate	B-VP	VBP	O	0	ROOT	-1
4	that	that	B-SBAR	IN	O	18	DEP	-1
5	endogenous	endogenous	B-NP	JJ	O	6	NMOD	-1
6	IL-1	IL-1	I-NP	NN	B-protein	7	SUB	-1
7	is	be	B-VP	VBZ	O	4	SBAR	-1
8	a	a	B-NP	DT	O	9	NMOD	-1
9	mediator	mediator	I-NP	NN	O	7	PRD	17	mediator
10	of	of	B-PP	IN	O	9	NMOD	-1
11	ischaemic	ischaemic	B-NP	JJ	O	13	AMOD	-1
12	and	and	I-NP	CC	O	13	AMOD	-1
13	excitotoxic	excitotoxic	I-NP	JJ	O	15	NMOD	-1
14	brain	brain	I-NP	NN	O	15	NMOD	-1
15	damage	damage	I-NP	NN	O	10	PMOD	6	damage
16	,	,	O	,	O	18	P	-1
17	and	and	O	CC	O	18	DEP	-1
18	that	that	B-SBAR	IN	O	3	VMOD	-1
19	inhibitors	inhibitor	B-NP	NNS	O	23	SUB	-1
20	of	of	B-PP	IN	O	19	NMOD	-1
21	IL-1	IL-1	B-NP	NN	B-protein	22	NMOD	-1
22	action	action	I-NP	NN	O	20	PMOD	0
23	may	may	B-VP	MD	O	18	SBAR	-1
24	be	be	I-VP	VB	O	23	VC	-1
25	of	of	B-PP	IN	O	24	PRD	-1
26	therapeutic	therapeutic	B-NP	JJ	O	27	NMOD	-1
27	value	value	I-NP	NN	O	25	PMOD	-1
28	in	in	B-PP	IN	O	24	VMOD	-1
29	the	the	B-NP	DT	O	30	NMOD	-1
30	treatment	treatment	I-NP	NN	O	28	PMOD	0
31	of	of	B-PP	IN	O	30	NMOD	-1
32	acute	acute	B-NP	JJ	O	36	NMOD	-1
33	or	or	I-NP	CC	O	36	NMOD	-1
34	chronic	chronic	I-NP	JJ	O	36	NMOD	-1
35	neuronal	neuronal	I-NP	JJ	O	36	NMOD	-1
36	death	death	I-NP	NN	O	31	PMOD	5	death
37	.	.	O	.	O	3	P	-1

